Filing Flows › PAVmed (PAVM) › Q2 2026
PAVmed (PAVM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
PAVmed (PAVM) reported revenue of $33K for the second quarter 2026 (Q2 2026), +450% from a year earlier and +50% from the quarter before.
PAVmed, Q2 2026: revenue $33K (+450% year over year), net loss $6.6M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $33K | +50% | +450% |
| Operating profit | −$7.0M | — | — |
| Net earnings | −$6.6M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $33K in Q2 2026, up 450% year over year and up 50% from the previous quarter.
Operating costs exceeded revenue by $7.0M, an operating margin of -21278.8%. Total costs grew 49% against revenue growth of 450%. The fastest-growing cost line was Cost of revenue (+198%). The quarter ended with a net loss of $6.6M, wider than the previous quarter's $1.1M loss. Minority interests bore $1.2M of it: to shareholders the quarter was a loss of $5.4M.
Operating cash flow was −$2.7M. Non-cash charges added back $19K of depreciation and amortization and $917K of share-based compensation. Working capital and other items added $3.0M. Capital expenditures of $13K exceeded it, leaving free cash flow of −$2.7M.
Questions
What was PAVmed's revenue in the second quarter 2026?
PAVmed (PAVM) reported revenue of $33K for the second quarter 2026 (Q2 2026), +450% from a year earlier and +50% from the quarter before.
Source: PAVmed 10-Q on SEC EDGAR.